LIXTE.jpg
LIXTE BIOTECHNOLOGY HOLDINGS REPORTS NEWLY PUBLISHED INDEPENDENT PRE-CLINICAL RESEARCH
14. Februar 2023 13:50 ET | Lixte Biotechnology Holdings, Inc.
THE RESEARCH SHOWS THAT PP2A, THE TARGET OF LIXTE’S LEAD CLINICAL COMPOUND, LB-100, WHEN DEFICIENT, ENHANCES EFFECTS OF IMMUNE CHECKPOINT BLOCKADE OF CANCER BY A PREVIOUSLY UNAPPRECIATED MECHANISM ...
OculosLogo_IntegratedInsight
Oculos and Optceutics Partner to Bring Expanded Services to Ophthalmic Innovators
26. April 2019 12:00 ET | iuvo bioscience
RUSH, N.Y. and LONDON, April 26, 2019 (GLOBE NEWSWIRE) -- Oculos (www.OculosCR.com), an industry-leading vertically-integrated ophthalmic R&D organization, and Optceutics (www.optceutics.com),...
eilber
Certis Oncology Announces CLIA Certification for High-Complexity Testing
16. Juli 2018 08:00 ET | Certis Oncology Solutions, Inc.
SAN DIEGO, July 16, 2018 (GLOBE NEWSWIRE) -- Certis Oncology Solutions, Inc., a new precision medicine company focused on individualized patient care, today announced that it has received its CLIA...
iuvo BioScience, Ind
iuvo BioScience, Industry-Leading Pre-Clinical Research Organization, Acquires Oculos Clinical Research
09. Juli 2018 10:00 ET | iuvo bioscience
RUSH, N.Y. and TAMPA, Fla., July 09, 2018 (GLOBE NEWSWIRE) -- iuvo BioScience, an industry leading R&D services company specializing in safety, microbiology, toxicology, and analytical chemistry...